A step forward in the treatment of chronic urticaria
It is estimated that 1 in 5 people will suffer from urticaria at some point in their lives. In Spain, 0.6 percent of the population experiences this condition in its chronic form.
2013-03-20
(Press-News.org) This press release is available in Spanish.
Barcelona, 20th March 2013.- An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.
Spontaneous chronic urticaria, one of the most common skin diseases, consists of an abrupt reaction that results in hives or stains of different shapes and sizes on the surface of the skin that grow and produce a very intense itch. Sufferers can develop dozens of hives each day for months or years. When the condition persists for more than 6 weeks, it is referred to as chronic urticaria and can last between approximately 5 and 10 years, adversely affecting the quality of life of the sufferer in both physical and emotional terms.
Approximately 50% of urticaria patients do not respond to treatment with standard doses of non-sedative antihistamines, and require a heavier dose of antihistamines. Some people even require immunosupressors, such as corticoids and cyclosporine A, to control the condition. These immunosupressors have significant side effects.
The study, in which Dr. Ana Giménez Arnau, a dermatologist at the Hospital del Mar and researcher with the group conducting research on inflammatory dermatological diseases at the IMIM (Hospital del Mar Medical Research Institute) was involved alongside institutions from Germany, the United States, and the United Kingdom, demonstrated that Omalizumab, a biological treatment that prevents immunoglobulin E from joining up with the receptor of the cells that triggers the urticaria, the mast cell, radically eliminates clinical symptoms (itching) and signs of urticaria (hives) in patients for whom antihistamines are ineffective.
The research, which has consisted of an international Phase III clinical trial conducted across several centres of research, has run for 7 months and involved 323 patients from different countries. These patients have an average age of 42 and for the most part are women (76%), a description that accurately reflects the profile of patients with chronic urticaria.
At 4-week intervals over a period of three months, participants were randomly given doses of 75,150, and 300mg of Omalizumab or a placebo drug using the double-blind method and their condition monitored. "In week 12, we can see a significant difference between the groups that receive doses of 150mg or 300mg of Omalizumab and those who receive a dose of 75mg or the placebo drug. The itching and the urticaria totally disappeared in 23% of patients administered a dose of 150mg, and in 53% of patients administered 300mg of Omalizumab", explains Dr. Giménez Arnau. She also adds that "the therapeutic objective is the full remission of symptoms in order to continue the therapy over a number of months before gradually phasing it out, resulting in the complete elimination of the disease".
This drug, for which US and European authorities will begin the registration process for treating this condition, is superior to the immunosupressors currently used to treat serious cases in its very fast effectiveness in 90% of patients and ease of use (once a month), as well as the fact that it has many fewer side effects. If registered, it could be available for use in treating chronic urticaria in 2014.
This is the first of three international clinical trials and, while the results thus far are very promising, further research is required to determine the exact role of this drug, its possible side effects, and the doses to be administered. This research gives hope to many people who have been waiting years for a solution, people who suffer with chronic urticaria on a daily basis and whose quality of life is greatly affected by the condition (itching, sleeplessness, psychiatric problems such as anxiety or depression), and a hope of eliminating the socioeconomic impact of the disease for society, since sufferers of chronic urticaria require constant medication to control the symptoms of their condition.
###
The study was coordinated by Genentech and Novartis Pharma.
Reference:
Omalizumab for the Treatment of ChronicIdiopathic or Spontaneous Urticaria. Maurer M., Rosen K., Hsieh H.J., Saini S., Grattan C., Giménez-Arnau A.M., Agarwal S., Doyle R., Canvin J., Kaplan A., and Casale T. New Engl J. Med. 2013. DOI: 10.1056/NEJMoa1215372 END
ELSE PRESS RELEASES FROM THIS DATE:
2013-03-20
NEW YORK (March 20, 2013) -- A multi-center analysis, led by Weill Cornell Medical College and published in the Journal of Clinical Gastroenterology, shows the use of temporary "fully covered self-expanding metal stents" (FCSEMS) can effectively fix a painful and potentially life-threatening benign biliary stricture -- a severely blocked or narrowed bile duct.
"Benign biliary strictures can be managed and resolved with these new fully covered metal stents with flared ends. Our study findings are similar to the recent European study results in patients overseas who received ...
2013-03-20
By charting the differing fates of individual T cells, researchers have shown that previously unpredictable aspects of the adaptive immune response can be effectively modeled. The crucial question: What determines which of the immune system's millions of cells will mobilize to fight an acute infection and which will be held back to survive long-term, forming the basis of the immunological memory? The scientists' findings, published in the journal Science, could have implications for improved immunotherapy and vaccination strategies.
The scientists found that the immediate ...
2013-03-20
HOUSTON – (March 20, 2013) – As Syria's raging civil war approaches the two-year mark, the United States should prepare a more focused strategy that strengthens the moderate political forces in Syria and engages Syria's regional and international stakeholders, according to a new special report from Rice University's Baker Institute for Public Policy. The report also recommends that U.S. strategy should buttress Syria's neighbors, address the deepening humanitarian crisis and plans for a post-Assad Syria.
The special report, "Syria at the Crossroads: United States Policy ...
2013-03-20
"We live in the post-genomic era, when DNA sequence data is growing exponentially", says Miami University (Ohio) computational biologist Iddo Friedberg. "But for most of the genes that we identify, we have no idea of their biological functions. They are like words in a foreign language, waiting to be deciphered." Understanding the function of genes is a problem that has emerged at the forefront of molecular biology. Many groups develop and employ sophisticated algorithms to decipher these "words". However, until now there was no comprehensive picture of how well these methods ...
2013-03-20
Norm Borin of California Polytechnic State University and Arline Savage of the School of Business at the University of Alabama at Birmingham, argue that the fictitious mining company in the 2009 James Cameron movie, Avatar, makes a perfect case study for how not to be a sustainable company and offers lesson to more down to earth corporations hoping to gain green credentials as opposed to the blues. We hear a lot about indigenous peoples (the Na'vi in the movie) whose health and lives are all but destroyed by invading corporations such as Resources Development Administration ...
2013-03-20
Sleep plays an important role in the brain's ability to consolidate learning when two new potentially competing tasks are learned in the same day, research at the University of Chicago demonstrates.
Other studies have shown that sleep consolidates learning for a new task. The new study, which measured starlings' ability to recognize new songs, shows that learning a second task can undermine the performance of a previously learned task. But this study is the first to show that a good night's sleep helps the brain retain both new memories.
Starlings provide an excellent ...
2013-03-20
This press release is available in French.
Montreal, March 20, 2013 – The aerospace industry is a key sector of the Canadian economy. With sales of over $22.4 billion in 2011, Canada ranks fourth globally in aerospace production. Nearly half of that revenue was generated in Quebec, where Montreal is one of the few places worldwide in which all the components needed to assemble an aircraft are available within a single metropolitan area.
To determine whether Canada can keep up with the global pace, Industry Canada commissioned a study to evaluate how well Canadian aerospace ...
2013-03-20
When Georgia Tech opens the doors to the Georgia Dome next month as the host institution for the 2013 Final Four, expect third-seeded Florida to walk out as the national champion. That's the prediction from Georgia Tech's Logistic Regression/Markov Chain (LRMC) college basketball ranking system, a computerized model that has chosen the men's basketball national champ in three of the last five years.
The LRMC predicts that Florida, Louisville, Indiana and Gonzaga are most likely to advance to the Final Four in Atlanta, with Florida and Gonzaga playing for the title on ...
2013-03-20
(SACRAMENTO, Calif.) -- New research from the UC Davis Comprehensive Cancer Center, published in the Journal of Surgical Research, may help clinicians determine which patients are at highest risk for post-surgical blood clots in the legs or lungs.
A team led by Robert Canter, UC Davis associate professor of surgery, studied the medical histories of more than 470,000 surgical patients to determine which factors increased their risk of blood clots, also called venous thromboembolism (VTE). The team then created a nomogram, a type of calculator, which can help clinicians ...
2013-03-20
URBANA - Although the 2012 drought in the Midwest may have dimmed the memories for some of the 2011 Ohio and Mississippi River flood, engineers, landowners, conservationists, crop scientists and soil scientists haven't forgotten. They are working hard to repair levees and restore the flood damaged Birds Point-New Madrid floodway in preparation for the next big flood which will eventually happen.
"After the waters recede, people forget about the catastrophic flooding and damage to agricultural lands, road infrastructure, homes, and businesses and the ongoing restoration ...
LAST 30 PRESS RELEASES:
[Press-News.org] A step forward in the treatment of chronic urticaria
It is estimated that 1 in 5 people will suffer from urticaria at some point in their lives. In Spain, 0.6 percent of the population experiences this condition in its chronic form.
